EGFR and lung carcinoma: Recently, a tumor-promoting role of Nrp2b has been described with expression associated with lung cancer development, progression [89,90], advanced stage, worse progression-free survival, increased PD-L1 levels, and acquisition of EGFR inhibitor resistance [90,97,98].